Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2014

View Archived Issues

Structure-based discovery of novel ITK inhibitors, GNE-9822 lead identified

A potent mGluR5 PAM shows promise in rodent cognition models

Results of a phase I dose-escalation study of a chikungunya virus vaccine

VX-787, first-in-class PB2 influenza polymerase inhibitor

arGEN-X reports preclinical data for ARGX-113

Glenmark Pharmaceuticals to begin IND-enabling studies of new bispecific antibody

Bristol-Myers Squibb and Celgene to evaluate immunotherapy/chemotherapy combination

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Pfizer and Crohn's & Colitis Foundation of America form IBD collaboration

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Illumina forms multiple collaborations for oncology genomics analysis

AM-9514, a GK activator with good pharmacokinetic profile in vivo

KalVista Pharmaceuticals confirms first-in-human trial of KVD-001

Potential AD treatment activates TGF-beta signaling pathway in the brain

Vertex Pharmaceuticals patents novel sodium channel blockers

Toyama designs novel antifungal agents

Researchers at Bayer Schering Pharma synthesize new products for cancer

Hanmi Pharm enters into agreement with Luye Pharma Group for poziotinib

Korean scientists present new anti-C5 MAbs

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Apixaban granted FDA approval for DVT and PE

EMA accepts Basilea Pharmaceutica's isavuconazole MAA for review

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

GSK to conduct phase II study of GSK-2862277 to prevent acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...